Tag: Alzheimer s treatment

While up to 20% of Alzheimer's patients may experience hallucinations as part of the disease, the question remains: can donepezil cause hallucinations or worsen them? This is a known, though uncommon, potential side effect of the medication [1.2.2, 1.4.1].

In clinical trials for donanemab (brand name Kisunla), approximately 37% of participants experienced amyloid-related imaging abnormalities (ARIA), a key safety consideration for this Alzheimer's treatment. Understanding **what are the side effects of the drug donanemab?** is crucial for patients, caregivers, and clinicians considering this therapy.

According to clinical trial data, approximately 26% of patients treated with LEQEMBI experienced infusion-related reactions. As part of these reactions, it is documented that **LEQEMBI affects blood pressure**, causing temporary fluctuations that may include either an increase or decrease. Healthcare providers closely monitor patients for these changes during and after the intravenous infusion.

In clinical trials for the Alzheimer's medication LEQEMBI (lecanemab), up to 12.6% of patients experienced brain swelling (ARIA-E) and 17.3% experienced brain bleeding (ARIA-H), which was higher than in the placebo group. While often asymptomatic, these side effects can, in rare cases, manifest with serious, stroke-like symptoms or lead to fatal brain hemorrhages, raising concerns about if **LEQEMBI can cause a stroke**. The U.S. Food and Drug Administration (FDA) has issued a black box warning to highlight this significant safety risk.

According to the Alzheimer's Association, millions of people in the United States live with Alzheimer's disease, and its prevalence is projected to increase significantly. For those with moderate to severe symptoms, a doctor may prescribe a combination of two medications, Aricept and memantine, to help manage cognitive and behavioral symptoms.

In the pivotal Clarity AD clinical trial, 12.6% of participants treated with Leqembi developed brain swelling (ARIA-E), a condition where confusion can be a key symptom [1.4.6]. The question of 'Can Leqembi cause confusion?' is directly linked to this and other potential side effects.

In clinical trials, common Leqembi side effects, such as infusion reactions and headaches, typically lasted for a few days to several weeks before resolving. However, the duration of side effects can vary significantly depending on the type and severity, with some serious adverse events like ARIA taking months to fully resolve.

Newly approved in 2024 for mild-to-moderate Alzheimer's disease, Zunveyl is a brand-name medication with a high average retail price that can exceed $900 per month without insurance. The final out-of-pocket cost for patients depends heavily on their insurance plan, discount programs, and assistance options.

As of 2016, the global burden of dementia was estimated at 43.8 million, highlighting the widespread need for effective treatments for cognitive decline. In this context, **Donepezil** (brand name Aricept) stands out as the most commonly used acetylcholinesterase inhibitor (AChEI) for treating the symptoms of Alzheimer's disease.

In clinical trials, approximately one-third of patients treated with tacrine, the active ingredient in Cognex, experienced reversible liver damage. For those interested in **what are the side effects of Cognex**, this serious issue, alongside other adverse reactions, ultimately led to the medication being withdrawn from the market.